Carcinoma, NeuroendocrinePhase 2NCT06406465
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Belinostat, Cisplatin, Etoposide
12 Phase 2 studies recruiting right now, most recently updated first.
Open the Phase 2 page · a list of only those studies
Triangle is made by Triangle Health, Inc.
Thyroid and neuroendocrine12 studies
Carcinoma, NeuroendocrinePhase 2NCT06406465
Belinostat, Cisplatin, Etoposide
Advanced Pheochromocytoma and ParagangliomaPhase 2NCT07282587
ONC206, ONC206: Dose 1, ONC206: Dose 2
PheochromocytomaPhase 2NCT03206060Papers
Lu-177-DOTATATE, Ga-68-DOTATATE
Pheochromocytoma/ParagangliomaPhase 2NCT04924075Papers
Belzutifan
Thyroid CancerPhase 2NCT06007924
Avutometinib, Defactinib
High Grade Neuroendocrine NeoplasmsPhase 2NCT06926634
Zanzalintinib
Neuroendocrine Tumor Grade 2Phase 2NCT04339036Papers
Capecitabine Oral Product, Temozolomide Oral Product, transarterial radioembolization
Locally Advanced Adrenal Cortical CarcinomaPhase 2NCT06900595
Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography
Neoadjuvant TreatmentPhase 2NCT06959511
Zanzalintinib
Metastatic Thyroid CancerPhase 2NCT03099356
Cyclophosphamide, Sirolimus
Differentiated Thyroid CancerPhase 2NCT06458036
Selpercatinib Monotherapy, 131I Therapy
Locally Advanced Differentiated Thyroid Gland CarcinomaPhase 2NCT06959641
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Survey Administration